Bookmark and Share

BioActivity Data for Compound Hexoprenaline (CID 325003)

BioActivity Outcomes:
Active(7)
 
 
Inactive(104)
 
 
Inconclusive(15)
 
 
Top Targets:
NR LBD PPAR(8)
 
 
 
NR LBD AR(7)
 
 
NR LBD ER(7)
 
 
NR LBD Fxr(4)
 
 
NR LBD GR(4)
 
 
BioAssay Types:
Confirmatory(82)
 
 
 
 
Summary(27)
 
 
 
Screening(10)
 
 
 
BioAssay Categories:
In vivo(1)
 
 
Toxicity(6)
 
 
 
 
Cell-based(8)
 
 
 
BioActivity Types:
Potency(97)
 
 
 
 
AC50(6)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 126    Data Row: 126   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID144206072]
Potency-Replicate_1 14.9601qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen [AID743064, Type: confirmatory]
View
2
[SID144206072]
Potency-Replicate_1 21.1317qHTS assay to identify aromatase inhibitors - cell viability counter screen [AID743084, Type: confirmatory]
View
3
[SID144206072]
Potency-Replicate_1 26.6032qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line [AID743012, Type: confirmatory]
View
4
[SID144206072]
Potency-Replicate_1 29.8493qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line [AID743014, Type: confirmatory]
View
5
[SID144206072]
Potency-Replicate_1 29.8493qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway [AID743065, Type: confirmatory]thyroid hormone receptor beta isoform 2 [Rattus norvegicus] [gi:399498506]
View
6
[SID170465755]
Ac50 44.6684qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel [AID1117312, Type: confirmatory]
View
7
[SID170465755]
GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen [AID1117336, Type: screening]
View
8
[SID144206072]
Potency 0.1117qHTS for Inhibitors of binding or entry into cells for Marburg Virus [AID720532, Type: confirmatory]gene 4 small orf - Marburg virus [Marburg marburgvirus] [gi:420597]
View
9
[SID170465755]
Ac50 0.630957qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel [AID1117310, Type: confirmatory]
View
10
[SID170465755]
AC50 (uM) 0.631qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel [AID1117298, Type: confirmatory]
View
11
[SID144206072]
Potency-Replicate_1 10.6717qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway [AID743075, Type: confirmatory]estrogen nuclear receptor alpha [Homo sapiens] [gi:348019627]
View
12
[SID170465755]
AC50 (uM) 39.8107qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel [AID1117304, Type: confirmatory]
View
13
[SID170465755]
Ac50 39.8107qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel [AID1117314, Type: confirmatory]
View
14
[SID170465755]
AC50 (uM) 44.6684qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel [AID1117305, Type: confirmatory]
View
15
[SID170465755]
nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen [AID1117326, Type: screening]
View
16
[SID170465755]
insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen [AID1117329, Type: screening]
View
17
[SID170465755]
VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen [AID1117340, Type: screening]
View
18
[SID170465755]
GLP1 secretion from NCI-H716 cells-screen [AID1117341, Type: screening]
View
19
[SID170465755]
HCT116 viability from Cell TiterGlo-screen [AID1117342, Type: screening]
View
20
[SID170465755]
SW480 viability from Cell TiterGlo-screen [AID1117343, Type: screening]
View